GLP-1 eligibility checker
See which criteria in US FDA labeling for GLP-1 medications match your BMI, age and health conditions. Informational only, not a treatment recommendation: decisions are made with your prescriber.
What this checker estimates
The GLP-1 Eligibility Checker compares your BMI, age, and comorbidities against current FDA labeling for Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro. Wegovy and Zepbound require BMI ≥30, or ≥27 with at least one weight-related condition. Zepbound was expanded in 2024 to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro carry an FDA-labeled indication only for type 2 diabetes, though the molecules (semaglutide, tirzepatide) are the same as Wegovy and Zepbound for weight management.
Who is this for?
Anyone trying to understand whether they are likely to qualify for a GLP-1 prescription before talking to a prescriber. The result is informational: your real eligibility depends on your full medical history, insurance plan rules, and your prescriber’s clinical judgment.
Frequently asked questions
What BMI qualifies for Wegovy or Zepbound?
FDA labeling requires BMI ≥30, OR BMI ≥27 with at least one weight-related condition (e.g., type 2 diabetes, hypertension, high cholesterol, OSA).
Can I get Ozempic or Mounjaro just for weight loss?
Ozempic and Mounjaro are FDA-approved for type 2 diabetes only. Their semaglutide/tirzepatide molecules are also sold as Wegovy and Zepbound for weight management. Off-label prescribing exists but coverage and access vary widely.
Does sleep apnea make me eligible for Zepbound?
Yes. In late 2024 the FDA expanded Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥30).
What if my BMI is just under 30?
BMI 27–29.9 plus at least one weight-related condition meets FDA labeling for Wegovy and Zepbound. Without a comorbidity, you generally do not meet labeled criteria.
Does insurance follow FDA labeling?
Not always. Many commercial plans require additional documentation (prior authorization, lifestyle attempts) or restrict GLP-1s to type 2 diabetes. In the US, Medicare follows its own rules: from July 2026 the Medicare GLP-1 Bridge lets eligible Part D patients get some GLP-1 medicines for weight management for no more than $50 a month, with clinical criteria (per Lilly, October 2026).
Related reading
Gila is coming to iPhone and Android
Your doses, meals, habits and food noise in one daily timeline. Join the waitlist and we’ll email you when it’s on your phone.
Join the waitlist